PRAGUE, Czech Republic, April 24, 2018 -- This week at the industry’s premier flow cytometry conference, CYTO 2018, Cytek Biosciences Inc. will be on the show floor highlighting its CytekTM Aurora flow cytometry system with enhanced features. This unique platform has been embraced by researchers around the world since making its debut at CYTO 2017, and the deployments so far have been validating the application flexibility of the Cytek Aurora. From extra-cellular vesicles to highly multiparametric applications beyond what were initially envisioned and more, the breadth of applications being performed on the Cytek Aurora continues to grow.
“At this time last year, we introduced the scientific community to an all-new full spectrum flow cytometer that enables new discoveries and deeper biological insights at an affordable cost,” noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. “Now, Cytek Aurora has been sold into four continents and is at work all over the globe. CYTO 2018 is the perfect place for us to showcase how we have expanded Cytek Aurora’s features and application abilities over the past year and set the stage for future innovations to come.”
Cytek Aurora offers capabilities that go beyond flow cytometry systems that come with a much higher price tag. With a simplified workflow, greater flexibility, and a lower cost of ownership, the Cytek Aurora is the embodiment of Cytek’s mission to make high end, high quality flow cytometry accessible to a larger number of researchers.
Cytek Aurora will be demonstrated at CYTO 2018 in Prague, Czech Republic, from April 28 – May 2 at booth #33. CYTO attendees are also encouraged to learn more about the Cytek Aurora through the following CYTO events and displays:
-
- Wednesday, May 2 – Commercial Tutorial: ‘Expanding Application Capabilities Using Full Spectrum Cytometry’
- Poster: ‘Minimizing the Effects of Spectral Overlap by Unmixing Versus Compensation,’ Program Number: 294. Poster Board Number: B289.
Please visit www.cytekbio.com for more information.
About Cytek Biosciences
Cytek Biosciences Inc. is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capability and a wide range of services to support researchers and clinicians. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. To learn more, visit www.cytekbio.com and follow them on LinkedIn.
Media Contact:
Justine Houston-Brown
Lages & Associates
(949) 453-8080
[email protected]
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/0c0b45d4-94bf-44ef-bcd8-8c3cf3b572ad


Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
How Marco Pharma International Preserves German Homeopathic Traditions in America
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 



